Hyaluronidase news

All news on Hyaluronidase (also known as Hyalase, Vitrase, and Amphadase): plants, production capacities, investments and involved companies.

6 November 2025
Johnson & Johnson's DARZALEX FASPRO®: First FDA-Approved Treatment for High-Risk Smoldering Multiple Myeloma
DARZALEX FASPRO® reduces progression risk to active multiple myeloma by 51% in high-risk patients, marking a shift in treatment strategy.
19 October 2025
Johnson & Johnson's Subcutaneous Amivantamab Shows 45% Response Rate in Head and Neck Cancer
Subcutaneous amivantamab offers rapid, durable responses in head and neck cancer, with 82% tumor shrinkage and a median response duration of 7.2 months.
14 October 2025
Genmab Reports Q3 2025 DARZALEX Sales of $3.67 Billion
Genmab earns royalties from DARZALEX sales, with $2.09B in the U.S. and $1.58B globally. The company focuses on innovative antibody therapeutics for cancer and serious diseases.
19 September 2025
Merck Gains EU CHMP Support for KEYTRUDA SC and New Head and Neck Cancer Use
CHMP backs KEYTRUDA SC for all EU adult indications and a new use in LA-HNSCC. Awaiting European Commission's final decision.

Who will be producing Hyaluronidase in the future?

Find out with chemXplore Analytics